In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride

To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity. Time-kill experiments were performed against four species (n=12) with besifloxacin, moxifloxacin and gatifloxac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of antimicrobial chemotherapy 2011-04, Vol.66 (4), p.840-844
Hauptverfasser: HAAS, Wolfgang, PILLAR, Chris M, HESJE, Christine K, SANFILIPPO, Christine M, MORRIS, Timothy W
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 844
container_issue 4
container_start_page 840
container_title Journal of antimicrobial chemotherapy
container_volume 66
creator HAAS, Wolfgang
PILLAR, Chris M
HESJE, Christine K
SANFILIPPO, Christine M
MORRIS, Timothy W
description To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity. Time-kill experiments were performed against four species (n=12) with besifloxacin, moxifloxacin and gatifloxacin, in the presence or absence of BAK, at t=0, 5, 15, 30, 45, 60, 120 and 360 min, according to standard CLSI methods. In the presence of BAK, bactericidal activity was observed within 5 min, regardless of the fluoroquinolone tested. The bactericidal activity of BAK was unaffected by the concurrent presence of besifloxacin and rapid killing (within 5 to 15 min) was not observed at BAK concentrations below 50 mg/L. However, when tested without BAK, besifloxacin was bactericidal in as little as 45 min, while moxifloxacin and gatifloxacin required at least 120 min; besifloxacin kill rates against fluoroquinolone-susceptible and -resistant strains were at least 2- to 4-fold faster than those of gatifloxacin or moxifloxacin. Besifloxacin was the most rapidly bactericidal fluoroquinolone tested, followed by gatifloxacin and moxifloxacin, both of which had similar activity. Our studies demonstrate that the previously reported rapid in vitro killing by gatifloxacin formulations was probably due to the concurrent presence of 50 mg/L BAK, which is much higher than the 3.2 mg/L BAK observed in human tears 1 min after instillation of ophthalmic gatifloxacin solutions [Friedlaender MH, Breshears D, Amoozgar B et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23: 835-41].
doi_str_mv 10.1093/jac/dkq531
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_954652554</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>954652554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-c43fd4da3e4571fe392bb951022632389d72040d037c1db65c2d7c9c2ddb23003</originalsourceid><addsrcrecordid>eNqFkc2KFDEURoMoTtu68QEkCCKI7SS5SaqylMGfgQE3ui5SScpOdyrpSarG1pUr38AX9EnM2O0MuBHCDV9y-CA5CD2m5BUlCk432pza7aUAegctKJdkxYiid9GCABGrhgs4QQ9K2RBCpJDtfXTCKCigii3Qj_OIr_yUE5786H59_7n1IWC337lcc5wK_uKnNe5d8UNIe218fInHtL9JWEeLP-vp9qCuae2w7ouLxv2532V3CGmoVfGbDtsU_Txisw4pe-seonuDDsU9Ou5L9Ontm49n71cXH96dn72-WBlO6VQnDJZbDY6Lhg4OFOt7JShhTAKDVtmGEU4sgcZQ20thmG2MqtP2DAiBJXp-6N3ldDm7MnWjL8aFoKNLc-mU4FIwIfh_yVY0TJFWXnc-_YfcpDnH-oyulVwpJqukJXpxgExOpWQ3dLv6wTp_7Sjpri121WJ3sFjhJ8fGuR-dvUH_aqvAsyOgi9FhyDoaX245UI1sQcBvwkqoCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>864992609</pqid></control><display><type>article</type><title>In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>HAAS, Wolfgang ; PILLAR, Chris M ; HESJE, Christine K ; SANFILIPPO, Christine M ; MORRIS, Timothy W</creator><creatorcontrib>HAAS, Wolfgang ; PILLAR, Chris M ; HESJE, Christine K ; SANFILIPPO, Christine M ; MORRIS, Timothy W</creatorcontrib><description>To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity. Time-kill experiments were performed against four species (n=12) with besifloxacin, moxifloxacin and gatifloxacin, in the presence or absence of BAK, at t=0, 5, 15, 30, 45, 60, 120 and 360 min, according to standard CLSI methods. In the presence of BAK, bactericidal activity was observed within 5 min, regardless of the fluoroquinolone tested. The bactericidal activity of BAK was unaffected by the concurrent presence of besifloxacin and rapid killing (within 5 to 15 min) was not observed at BAK concentrations below 50 mg/L. However, when tested without BAK, besifloxacin was bactericidal in as little as 45 min, while moxifloxacin and gatifloxacin required at least 120 min; besifloxacin kill rates against fluoroquinolone-susceptible and -resistant strains were at least 2- to 4-fold faster than those of gatifloxacin or moxifloxacin. Besifloxacin was the most rapidly bactericidal fluoroquinolone tested, followed by gatifloxacin and moxifloxacin, both of which had similar activity. Our studies demonstrate that the previously reported rapid in vitro killing by gatifloxacin formulations was probably due to the concurrent presence of 50 mg/L BAK, which is much higher than the 3.2 mg/L BAK observed in human tears 1 min after instillation of ophthalmic gatifloxacin solutions [Friedlaender MH, Breshears D, Amoozgar B et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23: 835-41].</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkq531</identifier><identifier>PMID: 21393192</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Aza Compounds - pharmacology ; Azepines - pharmacology ; Bacteria ; Bacteria - drug effects ; Benzalkonium Compounds - pharmacology ; Biological and medical sciences ; Body fluids ; Comparative analysis ; Drug Interactions ; Drug resistance ; Fluoroquinolones - pharmacology ; Medical sciences ; Microbial Viability - drug effects ; Pharmacology. Drug treatments ; Quinolines - pharmacology ; Time Factors</subject><ispartof>Journal of antimicrobial chemotherapy, 2011-04, Vol.66 (4), p.840-844</ispartof><rights>2015 INIST-CNRS</rights><rights>Copyright Oxford Publishing Limited(England) Apr 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-c43fd4da3e4571fe392bb951022632389d72040d037c1db65c2d7c9c2ddb23003</citedby><cites>FETCH-LOGICAL-c411t-c43fd4da3e4571fe392bb951022632389d72040d037c1db65c2d7c9c2ddb23003</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23976835$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21393192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HAAS, Wolfgang</creatorcontrib><creatorcontrib>PILLAR, Chris M</creatorcontrib><creatorcontrib>HESJE, Christine K</creatorcontrib><creatorcontrib>SANFILIPPO, Christine M</creatorcontrib><creatorcontrib>MORRIS, Timothy W</creatorcontrib><title>In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity. Time-kill experiments were performed against four species (n=12) with besifloxacin, moxifloxacin and gatifloxacin, in the presence or absence of BAK, at t=0, 5, 15, 30, 45, 60, 120 and 360 min, according to standard CLSI methods. In the presence of BAK, bactericidal activity was observed within 5 min, regardless of the fluoroquinolone tested. The bactericidal activity of BAK was unaffected by the concurrent presence of besifloxacin and rapid killing (within 5 to 15 min) was not observed at BAK concentrations below 50 mg/L. However, when tested without BAK, besifloxacin was bactericidal in as little as 45 min, while moxifloxacin and gatifloxacin required at least 120 min; besifloxacin kill rates against fluoroquinolone-susceptible and -resistant strains were at least 2- to 4-fold faster than those of gatifloxacin or moxifloxacin. Besifloxacin was the most rapidly bactericidal fluoroquinolone tested, followed by gatifloxacin and moxifloxacin, both of which had similar activity. Our studies demonstrate that the previously reported rapid in vitro killing by gatifloxacin formulations was probably due to the concurrent presence of 50 mg/L BAK, which is much higher than the 3.2 mg/L BAK observed in human tears 1 min after instillation of ophthalmic gatifloxacin solutions [Friedlaender MH, Breshears D, Amoozgar B et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23: 835-41].</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Aza Compounds - pharmacology</subject><subject>Azepines - pharmacology</subject><subject>Bacteria</subject><subject>Bacteria - drug effects</subject><subject>Benzalkonium Compounds - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Body fluids</subject><subject>Comparative analysis</subject><subject>Drug Interactions</subject><subject>Drug resistance</subject><subject>Fluoroquinolones - pharmacology</subject><subject>Medical sciences</subject><subject>Microbial Viability - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Quinolines - pharmacology</subject><subject>Time Factors</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2KFDEURoMoTtu68QEkCCKI7SS5SaqylMGfgQE3ui5SScpOdyrpSarG1pUr38AX9EnM2O0MuBHCDV9y-CA5CD2m5BUlCk432pza7aUAegctKJdkxYiid9GCABGrhgs4QQ9K2RBCpJDtfXTCKCigii3Qj_OIr_yUE5786H59_7n1IWC337lcc5wK_uKnNe5d8UNIe218fInHtL9JWEeLP-vp9qCuae2w7ouLxv2532V3CGmoVfGbDtsU_Txisw4pe-seonuDDsU9Ou5L9Ontm49n71cXH96dn72-WBlO6VQnDJZbDY6Lhg4OFOt7JShhTAKDVtmGEU4sgcZQ20thmG2MqtP2DAiBJXp-6N3ldDm7MnWjL8aFoKNLc-mU4FIwIfh_yVY0TJFWXnc-_YfcpDnH-oyulVwpJqukJXpxgExOpWQ3dLv6wTp_7Sjpri121WJ3sFjhJ8fGuR-dvUH_aqvAsyOgi9FhyDoaX245UI1sQcBvwkqoCw</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>HAAS, Wolfgang</creator><creator>PILLAR, Chris M</creator><creator>HESJE, Christine K</creator><creator>SANFILIPPO, Christine M</creator><creator>MORRIS, Timothy W</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride</title><author>HAAS, Wolfgang ; PILLAR, Chris M ; HESJE, Christine K ; SANFILIPPO, Christine M ; MORRIS, Timothy W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-c43fd4da3e4571fe392bb951022632389d72040d037c1db65c2d7c9c2ddb23003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Aza Compounds - pharmacology</topic><topic>Azepines - pharmacology</topic><topic>Bacteria</topic><topic>Bacteria - drug effects</topic><topic>Benzalkonium Compounds - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Body fluids</topic><topic>Comparative analysis</topic><topic>Drug Interactions</topic><topic>Drug resistance</topic><topic>Fluoroquinolones - pharmacology</topic><topic>Medical sciences</topic><topic>Microbial Viability - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Quinolines - pharmacology</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HAAS, Wolfgang</creatorcontrib><creatorcontrib>PILLAR, Chris M</creatorcontrib><creatorcontrib>HESJE, Christine K</creatorcontrib><creatorcontrib>SANFILIPPO, Christine M</creatorcontrib><creatorcontrib>MORRIS, Timothy W</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HAAS, Wolfgang</au><au>PILLAR, Chris M</au><au>HESJE, Christine K</au><au>SANFILIPPO, Christine M</au><au>MORRIS, Timothy W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>66</volume><issue>4</issue><spage>840</spage><epage>844</epage><pages>840-844</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity. Time-kill experiments were performed against four species (n=12) with besifloxacin, moxifloxacin and gatifloxacin, in the presence or absence of BAK, at t=0, 5, 15, 30, 45, 60, 120 and 360 min, according to standard CLSI methods. In the presence of BAK, bactericidal activity was observed within 5 min, regardless of the fluoroquinolone tested. The bactericidal activity of BAK was unaffected by the concurrent presence of besifloxacin and rapid killing (within 5 to 15 min) was not observed at BAK concentrations below 50 mg/L. However, when tested without BAK, besifloxacin was bactericidal in as little as 45 min, while moxifloxacin and gatifloxacin required at least 120 min; besifloxacin kill rates against fluoroquinolone-susceptible and -resistant strains were at least 2- to 4-fold faster than those of gatifloxacin or moxifloxacin. Besifloxacin was the most rapidly bactericidal fluoroquinolone tested, followed by gatifloxacin and moxifloxacin, both of which had similar activity. Our studies demonstrate that the previously reported rapid in vitro killing by gatifloxacin formulations was probably due to the concurrent presence of 50 mg/L BAK, which is much higher than the 3.2 mg/L BAK observed in human tears 1 min after instillation of ophthalmic gatifloxacin solutions [Friedlaender MH, Breshears D, Amoozgar B et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther 2006; 23: 835-41].</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>21393192</pmid><doi>10.1093/jac/dkq531</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0305-7453
ispartof Journal of antimicrobial chemotherapy, 2011-04, Vol.66 (4), p.840-844
issn 0305-7453
1460-2091
language eng
recordid cdi_proquest_miscellaneous_954652554
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects Anti-Bacterial Agents - pharmacology
Antibiotics
Antibiotics. Antiinfectious agents. Antiparasitic agents
Aza Compounds - pharmacology
Azepines - pharmacology
Bacteria
Bacteria - drug effects
Benzalkonium Compounds - pharmacology
Biological and medical sciences
Body fluids
Comparative analysis
Drug Interactions
Drug resistance
Fluoroquinolones - pharmacology
Medical sciences
Microbial Viability - drug effects
Pharmacology. Drug treatments
Quinolines - pharmacology
Time Factors
title In vitro time―kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T19%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20time%E2%80%95kill%20experiments%20with%20besifloxacin,%20moxifloxacin%20and%20gatifloxacin%20in%20the%20absence%20and%20presence%20of%20benzalkonium%20chloride&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=HAAS,%20Wolfgang&rft.date=2011-04-01&rft.volume=66&rft.issue=4&rft.spage=840&rft.epage=844&rft.pages=840-844&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkq531&rft_dat=%3Cproquest_cross%3E954652554%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=864992609&rft_id=info:pmid/21393192&rfr_iscdi=true